Patients with Multiple Sclerosis Show Robust T-Cell Responses to mRNA COVID-19 Vaccines

New research shows that Multiple Sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment – which depletes the B cells that contribute to the MS attacks – are able to mount robust T-cell responses to the mRNA COVID-19 vaccines, despite having a muted antibody response to the vaccines.

2022 Breakthrough Prize in Life Sciences Awarded to Penn Medicine mRNA Pioneers Drew Weissman and Katalin Karikó

PHILADELPHIA – It was a scientific discovery 16 years ago that paved the way for creation of lifesaving vaccines when the COVID-19 pandemic spread across the globe in 2020. Now, the two Penn Medicine researchers behind the findings are again being recognized for their innovative and monumental work, which has ushered in a new era of vaccine technology.

Penn mRNA Researchers Drew Weissman and Katalin Karikó Awarded the 2021 Albany Prize

PHILADELPHIA – For their landmark research that set a foundation for the mRNA SARS-CoV-2 vaccines, Drew Weissman, MD, PhD, the Roberts Family Professor of Vaccine Research, and Katalin Karikó;, PhD, an adjunct professor of Neurosurgery at the Perelman School of Medicine at the University of Pennsylvania and a senior vice president at BioNTech, have been selected to receive the 2021 Albany Prize.

Chula Innovations for Society to Fight COVID-19

Chulalongkorn University has taken a bold step in commutating its transformation to an innovation-centric university with its “Innovations for Society” campaign. The campaign uses a short movie to inform the public about the various innovations that Chula has successfully developed to fight the COVID-19 pandemic, as part of Chula’s mission to play a leading role in “Creating Knowledge and Innovation to Promote Sustainable Development for Society”.